Clinical Trials

102 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT06136650 2026-04-21

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06952803 2026-04-21

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT02913196 2026-04-20

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Phase 1 Completed

16 enrolled

Prostate Cancer Metastatic

NCT06378866 2026-04-20

DIVINE

532 enrolled

Prostatic Neoplasms

NCT06925737 2026-04-20

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT05848011 2026-04-17

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06353386 2026-04-17

MK-5684-01A

Phase 1/2 Recruiting

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT07237269 2026-04-15

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT07225946 2026-04-14

KLK2-PASenger

800 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02123758 2026-04-13

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02257736 2026-04-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT03431350 2026-04-13

QUEST

136 enrolled 29 charts

Phase 3 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-04-13

MAGNITUDE

765 enrolled 16 charts 2 FDA

Phase 3 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-04-13

AMPLITUDE

696 enrolled 15 charts 2 FDA

Phase 1 Active not recruiting

Metastatic Castration-sensitive Prostate Cancer

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-04-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT04633252 2026-04-08

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

86 enrolled

Prostatic Neoplasms

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

464 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06392841 2026-04-08

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT07005154 2026-04-02

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT03419234 2026-04-01

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

223 enrolled 14 charts